Foresite Capital Raises $300M Fund Focused On Life Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
San Francisco-based VC also is an investor in a $200 million Series DD funding for type 2 diabetes-focused Intarcia Therapeutics. Foresite will use the same investment strategy for its second fund, seeking late-stage investments in proven technologies with strong management and promising market positions.
You may also be interested in...
Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013
Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.
Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.